Yazar "Çeken, Sabahat" seçeneğine göre listele

Listeleniyor 1 - 1 / 1
  • Küçük Resim
    Öğe
    Switching to tenofovir alafenamide in hbv: nationwide real life data of efficacy and safety from Turkey
    (Wiley, 2021) Tabak, Fehmi; Yörük, Gülşen; Köksal, İftihar; Erdem, Hazal; Yıldız, Dilek; İnce, Nevin; Yamazhan, Tansu; Sume, Serkan; Batırel, Ayşe; Günal, Özgür; Yıldız, İlknur Esen; Sırmatel, Fatma; Koç, Meliha Merih; Çeken, Sabahat; Bozkurt, İlkay; Görenek, Levent; Şener, Alper; Köse, Şükran; Türker, Kamuran; İnan, Dilara; Karabay, Oğuz; Güner, Rahmet
    Tenofovir alafenamide (TAF) is a new prodrug of tenofovir used for the treatment of HIV-1 and HBV infections. It provides more efficient intracellular tenofovir concentrations at a relatively lower dose than provided by tenofovir disoproxil fumarate (TDF). TAF is expected to have efficacy similar to that of TDF with improved safety profile.